Cisplatin augments FAS-mediated apoptosis through lipid rafts

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2065-2071

  Huang, Cheng Ri ^a   Jin, Zhe Xiong ^a   Dong, Lingli ^a,b   Tong, Xiao Peng ^a   Yue, Sun ^a   Kawanami, Takafumi ^a   Sawaki, Toshioki ^a   Sakai, Tomoyuki ^a   Miki, Miyuki ^a   Iwao, Haruka ^a   Nakajima, Akio ^a   Masaki, Yasufumi ^a   Fukushima, Yoshihiko ^a   Tanaka, Masao ^a   Fujita, Yoshimasa ^a   Nakajima, Hideo ^a   Okazaki, Toshiro ^c   Umehara, Hisanori ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cisplatin; FAS; Lipid rafts; Sphingomyelin

Indexed keywords

CASPASE 3; CASPASE 8; CH 11; CISPLATIN; COMPLEMENTARY DNA; FAS ANTIBODY; FAS ANTIBODY CH 11; IMMUNOGLOBULIN M; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; LIPID RAFT; LYMPHOMA CELL; MOUSE; NONHUMAN; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; CELL SURVIVAL; CISPLATIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; MEMBRANE MICRODOMAINS;

EID: 77955071563     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, Tsien RY and Lenardo MJ: FAS preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288: 2354-2357, 2000.
2. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL and Lenardo MJ: A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288: 2351-2354, 2000.
3. Gajate C and Mollinedo F: The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of FAS/CD95 into membrane rafts in human leukemic cells. Blood 98: 3860-3863, 2001.
4. Grassme H, Jendrossek V, Riehle A, von Kurthy G, Berger J, Schwarz H, Weller M, Kolesnick R and Gulbins E: Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 9: 322-330, 2003.
5. Hueber A-O, Bernard A-M, Herincs Z, Couzinet A and He H-T: An essential role for membrane rafts in the initiation of FAS/CD95-triggered cell death in mouse thymocytes. EMBO Rep 31: 190-196, 2002.
6. Simons K and Vaz WL: Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct 33: 269-295, 2004.
7. Miyaji M, Jin ZX, Yamaoka S, Amakawa R, Fukuhara S, Sato SB, Kobayashi T, Domae N, Mimori T, Bloom ET, Okazaki T and Umehara H: Role of membrane sphingomyelin and ceramide in platform formation for FAS-mediated apoptosis. J Exp Med 202: 249-259, 2005.
8. Fuertesa MA, Castillab J, Alonsoa C and Perez JM: Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med 10: 257-266, 2003.
9. Spierings DC, de Vries EG, Vellenga E and de Jong S : Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line. Cell Death Differ 10: 808-822, 2003
10. Micheau O, Solary E, Hammann A and Dimanche-Boitrel MT: FAS ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 274: 7989-7992, 1999.
11. Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N and Tasaka K: Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol 45: 199-206, 2000.
12. Bollinger CR, Teichgraber V and Gulbins E: Ceramide-enriched membrane domains. Biochim Biophys Acta 1746: 284-294, 2005.
13. Rebillard A, Tekpli X, Meurette O, Sergent O, LeMoigne-Muller G, Vernhet L, Gorria M, Chevanne M, Christmann M, Kaina B, Counillon L, Gulbins E, Lagadic-Gossmann D and Dimanche-Boitrel MT: Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res 67: 7865-7874, 2007.
14. Yamaoka S, Miyaji M, Kitano T, Umehara H and Okazaki T: Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-deficient cells. J Biol Chem 279: 18688-18693, 2004.
15. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y and Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate Apoptosis. Cell Death Differ 66: 233-243, 1991.
16. Umehara H, Huang JY, Kono T, Tabassam FH, Okazaki T, Bloom ET and Domae N: Involvement of protein tyrosine kinase p72syk and phosphatidylinositol-3- kinase in CD2-mediated granular exocytosis in natural killer cell line. J Immunol 159: 1200-1207, 1997.
17. Umehara H, Huang JY, Kono T, Tabassam FH, Okazaki T, Gouda S, Nagano Y, Bloom ET and Domae N: Co-stimulation of T-cells with CD2 augments TCR-CD3-mediated activation of protein tyrosine kinase p72syk, resulting in increased tyrosine phosphorylation of adapter proteins, ShC and Cbl. Int Immunol 10: 833-845, 1998.
18. Fox SA, Kusmiaty LSS, Dharmarajan AM and Garlepp MJ: Cisplatin and TNF-α down-regulate transcription of Bcl-xL in murine malignant mesothelioma cells. Biochem Biophys Res Commun 337: 983-991, 2005.
19. Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O, Laurent G, Gambert P, Solary E and Dimanche-Boitrel MT: Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 64: 3593-3598, 2004.
20. Scaffidi C, Fulda S, Srinivasan A, Friesen CLF, Tomaselli KJ, Debatin K-M, Krammer PH and Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687, 1998.
21. Wajant H: The FAS signaling pathway: More than a paradigm. Science 296: 1635-1636, 2002.
22. Scott F, Stec B, Pop C, Dobaczewska M, Lee J, Monosov E, Robinson H, Salvesen G, Schwarzenbacher R and Riedl S: The FAS-FADD death domain complex structure unravels signalling by receptor clustering. Nature 457: 1019-1022, 2009.
23. Green DR and Evan GI: A matter of life and death. Cancer Cell 1: 19-30, 2002.
24. Jamieson ER and Lippard SJ: Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev 99: 2467-2498, 1999.
25. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588, 1995.
26. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E and Dimanche-Boitrel MT: Anticancer agents sensitize tumor cells to TRAIL-mediated caspase-8 activation and apoptosis. Cancer Res 61: 1645-1651, 2001.
27. Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E and Dimanche-Boitrel MT: Chemotherapy enhances TNF-related apoptosis-inducing ligand death inducing signaling complex assembly in HT29 human colon cancer cells. Oncogene 22: 1807-1816, 2003.
28. Cherukuri A, Dykstra M and Pierce SK: Floating the raft hypothesis: Lipid rafts play a role in immune cell activation. Immunity 14: 657-660, 2001.
29. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM and Dustin ML: The immunological synapse. Annu Rev Immunol 19:375-396, 2001.
30. Davis DM: Assembly of the immunological synapse for T-cell and NK cells. Trends Immunol 23: 356-363, 2002.
31. Dykstra M, Cherukuri A, Sohn HW, Tzeng SJ and Pierce SK: Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol 21: 457-481, 2003.
32. Muppidi J and Siegel RM: Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic death. Nat Immunol 5: 182-189, 2004.
33. Jin ZX, Huang CR, Dong L, Goda S, Kawanami T, Sawaki T, Sakai T, Tong XP, Masaki Y, Fukushima T, Tanaka M, Mimori T, Toho H, Bloom ET, Okazaki T and Umehara H: Impaired TCR signaling through dysfunction of lipid rafts in sphingomyelin synthese 1 (SMS1)-knock down T-cells. Int Immunol 20: 1427-1437, 2008.
34. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2272: 65-79, 2003.